Tailoring therapy in colorectal cancer by PET-CT

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 53, Issue 2, 2009, Pages 224-244

  Vriens, D ^a   De Geus Oei, L F ^a   Van Der Graaf, W T A ^b   Oyen, W J G ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Department of Medical Oncology ^*  (Netherlands)

Author keywords

Leukocytes; Radiolabelling; Radionuclide imaging

Indexed keywords

CAPECITABINE; CARBOPLATIN; CARCINOEMBRYONIC ANTIGEN; FLUORODEOXYGLUCOSE F 18; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MITOMYCIN C; OXALIPLATIN; TEGAFUR; URACIL;

CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER THERAPY; CLINICAL ASSESSMENT; CLINICAL EVALUATION; COLORECTAL CARCINOMA; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; HUMAN; LIVER METASTASIS; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PROGNOSIS; RECTUM CANCER; REVIEW; SYSTEMATIC REVIEW; TREATMENT RESPONSE; COLORECTAL TUMOR; METHODOLOGY; PATHOLOGY; RECURRENT DISEASE; TREATMENT OUTCOME;

COLORECTAL NEOPLASMS; HUMANS; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; RECURRENCE; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 69449094224     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (107)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
2. Ries L, Melbert D, Krapcho M, Stinchcomb D, Howlader N, Horner M, et al. SEER Cancer Statistics Review, 1975-2005, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975-2005/, based on November 2007 SEER data submission, posted to the SEER web site; 2008.
3. Punt CJ. New options and old dilemmas in the treatment of patients with advanced colorectal cancer. Ann Oncol 2004;15:1453-9.
4. Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008;26:2013-9.
5. Mijnhout GS, Riphagen, II, Hoekstra OS. Update of the FDG PET search strategy. Nucl Med Commun 2004;25:1187-9.
6. Newcombe RG. Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med 1998;17:857-72.
7. Davey K, Heriot AG, Mackay J, Drummond E, Hogg A, Ngan S et al. The impact of 18-fluorodeoxyglucose positron emission tomography-computed tomography on the staging and management of primary rectal cancer. Dis Colon Rectum 2008;51:997-1003.
8. Gearhart SL, Frassica D, Rosen R, Choti M, Schulick R, Wahl R. Improved staging with pretreatment positron emission tomography/computed tomography in low rectal cancer. Ann Surg Oncol 2006;13:397-404.
9. Heriot AG, Hicks RJ, Drummond EG, Keck J, Mackay J, Chen F et al. Does positron emission tomography change management in primary rectal cancer? A prospective assessment. Dis Colon Rectum 2004; 47:451-8.
10. Bassi MC, Turri L, Sacchetti G, Loi G, Cannillo B, La Mattina P et al. FDG-PET/CT imaging for staging and target volume delineation in preoperative conformai radiotherapy of rectal cancer. Int J Radiat Oncol Biol Phys 2008;70:1423-6.
11. Furukawa H, Ikuma H, Seki A, Yokoe K, Yuen S, Aramaki T et al. Positron emission tomography scanning is not superior to whole body multidetector helical computed tomography in the preoperative staging of colorectal cancer. Gut 2006;55:1007-11.
12. Park IJ, Kim HC, Yu CS, Ryu MH, Chang HM, Kim JH et al. Efficacy of PET/CT in the accurate evaluation of primary colorectal carcinoma. Eur J Surg Oncol 2006;32:941-7.
13. Kantorova I, Lipska L, Belohlavek O, Visokai V, Trubac M, Schneiderova M. Routine (18)F-FDG PET preoperative staging of colorectal cancer: comparison with conventional staging and its impact on treatment decision making. J Nucl Med 2003;44:1784-8.
14. Veit-Haibach P, Kuehle CA, Beyer T, Stergar H, Kuehl H, Schmidt J et al. Diagnostic accuracy of colorectal cancer staging with whole-body PET/CT colonography. JAMA 2006;296:2590-600.
15. Llamas-Elvira JM, Rodriguez-Fernandez A, Gutierrez-Sainz J, Gomez-Rio M, Bellon-Guardia M, Ramos-Font C et al. Fluorine-18 fluorodeoxyglucose PET in the preoperative staging of colorectal cancer. Eur J Nucl Med Mol Imaging 2007;34:859-67.
16. Glimelius B, Oliveira J. Rectal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008;19 Suppl 2:ii31-2.
17. Van Cutsem EJ, Oliveira J. Colon cancer: ESMO clinical recommendations for diagnosis, adjuvant treatment and follow-up. Ann Oncol 2008;19 Suppl 2:ii29-30.
18. Van Cutsem EJ, Oliveira J. Advanced colorectal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008;19 Suppl 2:ii33-4.
19. 18F]fluorodeoxyglucose in recurrent colorectal cancer. Br J Surg 1994;81:1666-70.
20. Simo M, Lomena F, Setoain J, Perez G, Castellucci P, Costansa JM et al. FDG-PET improves the management of patients with suspected recurrence of colorectal cancer. Nucl Med Commun 2002;23:975-82.
21. Scott AM, Gunawardana DH, Kelley B, Stuckey JG, Byrne AJ, Ramshaw JE et al. PET changes management and improves prognostic stratification in patients with recurrent colorectal cancer: results of a multicenter prospective study. J Nucl Med 2008;49:1451-7.
22. Selvaggi F, Cuocolo A, Sciaudone G, Maurea S, Giuliani A, Mainolfi C. FGD-PET in the follow-up of recurrent colorectal cancer. Colorectal Dis 2003;5:496-500.
23. Flamen P, Hoekstra OS, Homans F, Van Cutsem E, Maes A, Stroobants S et al. Unexplained rising carcinoembryonic antigen (CEA) in the postoperative surveillance of colorectal cancer: the utility of positron emission tomography (PET). EurJ Cancer 2001;37:862-9.
24. Flamen P, Stroobants S, Van Cutsem E, Dupont P, Bormans G, De Vadder N et al. Additional value of whole-body positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D-glucose in recurrent colorectal cancer. J Clin Oncol 1999;17:894-901. (Pubitemid 29109320)
25. 18F]fluorodeoxyglucose in management of recurrent colorectal cancer. Arch Surg 1999;134:503-11; discussion 11-3.
26. Even-Sapir E, Parag Y, Lerman H, Gutman M, Levine C, Rabau M et al. Detection of recurrence in patients with rectal cancer: PET/CT after abdominoperineal or anterior resection. Radiology 2004;232:815-22.
27. 18F-FDG-PET in the suspicion of recurrent colorectal cancer based on asymptomatically elevated serum level of carcinoembryonic antigen (CEA) in Taiwan. Hepatogastroenterology 2006;53:348-50.
28. Faneyte IF, Dresen RC, Edelbroek MA, Nieuwenhuijzen GA, Rutten HJ. Pre-operative staging with positron emission tomography in patients with pelvic recurrence of rectal cancer. Dig Surg 2008;25:202-7.
29. Kalff V, Hicks RJ, Ware RE, Hogg A, Binns D, McKenzie AF. The clinical impact of (18)F-FDG PET in patients with suspected or confirmed recurrence of colorectal cancer: a prospective study. J Nucl Med 2002;43:492-9.
30. Wiering B, Krabbe PF, Jager GJ, Oyen WJ, Ruers TJ. The impact of fluor-18-deoxyglucose-positron emission tomography in the management of colorectal liver metastases. Cancer 2005;104:2658-70.
31. 18F] fluorodeoxyglucose in identifying operable colorectal cancer metastases to the liver. Arch Surg 1996;131:703-7. (Pubitemid 26243630)
32. Vitola JV, Delbeke D, Sandler MP, Campbell MG, Powers TA, Wright JK et al. Positron emission tomography to stage suspected metastatic colorectal carcinoma to the liver. Am J Surg 1996;171:21-6.
33. Ogunbiyi OA, Flanagan FL, Dehdashti F, Siegel BA, Trask DD, Birnbaum EH et al. Detection of recurrent and metastatic colorectal cancer: comparison of positron emission tomography and computed tomography. Ann Surg Oncol 1997;4:613-20.
34. 18F-FDG positron emission tomography scanning on selection of patients for resection of hepatic colorectal metastases. Am J Surg 1999;178:282-7.
35. Zhuang H, Sinha P, Pourdehnad M, Duarte PS, Yamamoto AJ, Alavi A. The role of positron emission tomography with fluorine-18-deoxyglucose in identifying colorectal cancer metastases to liver. Nucl Med Commun 2000;21:793-8.
36. Strasberg SM, Dehdashti F, Siegel BA, Drebin JA, Linehan D. Survival of patients evaluated by FDG-PET before hepatic resection for metastatic colorectal carcinoma: a prospective database study. Ann Surg 2001;233:293-9.
37. Topal B, Flamen P, Aerts R, D'Hoore A, Filez L, Van Cutsem E et al. Clinical value of whole-body emission tomography in potentially curable colorectal liver metastases. Eur J Surg Oncol 2001;27:175-9.
38. Ruers TJ, Langenhoff BS, Neeleman N, Jager GJ, Strijk S, Wobbes T et al. Value of positron emission tomography with [F-18]fluorodeoxyglucose in patients with colorectal liver metastases: a prospective study. J Clin Oncol 2002;20:388-95.
39. Arulampalam TH, Francis DL, Visvikis D, Taylor I, Ell PJ. FDG-PET for the pre-operative evaluation of colorectal liver metastases. EurJ Surg Oncol 2004;30:286-91.
40. Bohm B, Voth M, Geoghegan J, Hellfritzsch H, Petrovich A, Scheele J et al. Impact of positron emission tomography on strategy in liver resection for primary and secondary liver tumors. J Cancer Res Clin Oncol 2004;130:266-72.
41. Rosa F, Meimarakis G, Stahl A, Bumm R, Hahn K, Tatsch K et al. Colorectal cancer patients before resection of hepatic metastases. Impact of (18)F-FDG PET on detecting extrahepatic disease. Nuklearmedizin 2004;43:135-40.
42. Selzner M, Hany TF, Wildbrett P, McCormack L, Kadry Z, Clavien PA. Does the novel PET/CT imaging modality impact on the treatment of patients with metastatic colorectal cancer of the liver? Ann Surg 2004;240:1027-34; discussion 35-6.
43. Teague BD, Morrison CP, Court FG, Chin VT, Costello SP, Kirkwood ID et al. Role of FDG-PET in surgical management of patients with colorectal liver metastases. ANZ J Surg 2004;74:646-52.
44. 18F]fluoro-2-deoxy-D-glucose positron emission tomography of resectable colorectal liver metastases. Br J Surg 2005;92:362-9.
45. 18F-fluorodeoxy-glucose on therapeutic decisions. Nuklearmedizin 2006;45:177-84.
46. Joyce DL, Wahl RL, Patel PV, Schulick RD, Gearhart SL, Choti MA. Preoperative positron emission tomography to evaluate potentially resectable hepatic colorectal metastases. Arch Surg 2006;141:1220-6; discussion 7.
47. Khan S, Tan YM, John A, Isaac J, Singhvi S, Guest P et al. An audit of fusion CT-PET in the management of colorectal liver metastases. Eur J Surg Oncol 2006;32:564-7.
48. 18F-FDG PET/CT in patients with liver metastases. Eur J Nucl Med Mol Imaging 2007;34:1906-14.
49. Denecke T, Steffen I, Hildebrandt B, Ruhl R, Streitparth F, Lehmkuhl L et al. Assessment of local control after laser-induced thermotherapy of liver metastases from colorectal cancer: contribution of FDG-PET in patients with clinical suspicion of progressive disease. Acta Radiol 2007;48:821-30.
50. Huguet EL, Old S, Praseedom RK, Balan KK, Gibbs P, Jamieson NV. F18-FDG-PET evaluation of patients for resection of colorectal liver metastases. Hepatogastroenterology 2007;54:1667-71. (Pubitemid 350068450)
51. 18F-FDG PET/CT in colorectal liver metastases - comparison with CT and liver MRI. Eur J Nucl Med Mol Imaging 2008;35:1323-9.
52. Sørensen M, Mortensen FV, Høyer M, Vilstrup H, Keiding S. FDG-PET improves management of patients with colorectal liver metastases allocated for local treatment: a consecutive prospective study. Scand J Surg 2007;96:209-13.
53. Wiering B, Krabbe PF, Dekker HM, Oyen WJ, Ruers TJ. The role of FDG-PET in the selection of patients with colorectal liver metastases. Ann Surg Oncol 2007;14:771-9.
54. Pawlik TM, Assumpcao L, Vossen JA, Buijs M, Gleisner AL, Schulick RD et al. Trends in nontherapeutic laparotomy rates in patients undergoing surgical therapy for hepatic colorectal metastases. Ann Surg Oncol 2009;16:371-8.
55. Fernandez FG, Drebin JA, Linehan DC, Dehdashti F, Siegel BA, Strasberg SM. Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET). Ann Surg 2004;240:438-47; discussion 47-50.
56. Feinstein AR, Sosin DM, Wells CK. The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. N Engl J Med 1985;312:1604-8.
57. 18F] fluorodeoxyglucose positron emission tomography in the detection of colorectal metastases. J Clin Oncol 2005;23:8713-6.
58. Delbeke D, Vitola JV, Sandier MP, Arildsen RC, Powers TA, Kelly Wright J et al. Staging recurrent metastatic colorectal carcinoma with PET. J Nucl Med 1997;38:1196-201.
59. Ruhlmann J, Schomburg A, Bender H, Oehr P, Robertz-Vaupel GM, Vaupel H et al. Fluorodeoxyglucose whole-body positron emission tomography in colorectal cancer patients studied in routine daily practice. Dis Colon Rectum 1997;40:1195-204.
60. 18F-FDG-positron emission tomography for decision making in colorectal cancer recurrences. Langenbecks Arch Surg 2000;385:129-34.
61. Whiteford MH, Whiteford HM, Yee LF, Ogunbiyi OA, Dehdashti F, Siegel BA et al. Usefulness of FDG-PET scan in the assessment of suspected metastatic or recurrent adenocarcinoma of the colon and rectum. Dis Colon Rectum 2000;43:759-67; discussion 67-70.
62. Arulampalam T, Costa D, Visvikis D, Boulos P, Taylor I, Ell P. The impact of FDG-PET on the management algorithm for recurrent colorectal cancer. Eur J Nucl Med 2001;28:1758-65.
63. Desai DC, Zervos EE, Arnold MW, Burak WE, Jr., Mantil J, Martin EW, Jr. Positron emission tomography affects surgical management in recurrent colorectal cancer patients. Ann Surg Oncol 2003;10:59-64.
64. Nakamoto Y, Sakamoto S, Okada T, Senda M, Higashi T, Saga T et al. Clinical value of manual fusion of PET and CT images in patients with suspected recurrent colorectal cancer. AJR Am J Roentgenol 2007;188:257-67.
65. Akiyoshi T, Oya M, Fujimoto Y, Kuroyanagi H, Ueno M, Yamaguchi T et al. Comparison of preoperative whole-body positron emission tomography with MDCT in patients with primary colorectal cancer. Colorectal Dis 2008 [Epub ahead of print].
66. Huebner RH, Park KC, Shepherd JE, Schwimmer J, Czernin J, Phelps ME et al. A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer. J Nucl Med 2000;41:1177-89. (Pubitemid 30464000)
67. 18FDG-PET in the follow-up of patients with colorectal cancer. Br J Cancer 2008;98:875-80.
68. Fukunaga H, Sekimoto M, Ikeda M, Higuchi I, Yasui M, Seshimo I et al. Fusion image of positron emission tomography and computed tomography for the diagnosis of local recurrence of rectal cancer. Ann Surg Oncol 2005;12:561-9.
69. 18F-FDG positron emission tomography staging and restaging in rectal cancer treated with preoperative chemoradiation. Int J Radiat Oncol Biol Phys 2004;58:528-35.
70. 18F-FDG PET kinetics in patients with metastatic colorectal carcinoma receiving FOLFOX chemotherapy. J Nucl Med 2004;45:1480-7.
71. de Geus-Oei LF, Wiering B, Krabbe PF, Ruers TJ, Punt CJ, Oyen WJ. FDG-PET for prediction of survival of patients with metastatic colorectal carcinoma. Ann Oncol 2006;17:1650-5.
72. 18F-FDG PET scanning correlates with tissue markers of poor prognosis and predicts mortality for patients after liver resection for colorectal metastases. J Nucl Med 2007;48:771-5.
73. Oku S, Nakagawa K, Momose T, Kumakura Y, Abe A, Watanabe T et al. FDG-PET after radiotherapy is a good prognostic indicator of rectal cancer. Ann Nucl Med 2002;16:409-16. (Pubitemid 35407630)
74. Dimitrakopoulou-Strauss A, Strauss LG, and Rudi J. PET-FDG as predictor of therapy response in patients with colorectal carcinoma. Q J Nucl Med 2003;47:8-13. (Pubitemid 36826756)
75. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
76. Eisenhauer EA Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47.
77. Engenhart R, Kimmig BN, Strauss LG, Hover KH, Romahn J, Haberkorn U et al. Therapy monitoring of presacral recurrences after high-dose irradiation: value of PET, CT, CEA and pain score. Strahlenther Onkol 1992;168:203-12.
78. Denecke T, Rau B, Hoffmann KT, Hildebrandt B, Ruf J, Gutberiet M et al. Comparison of CT, MRI and FDG-PET in response prediction of patients with locally advanced rectal cancer after multimodal preoperative therapy: is there a benefit in using functional imaging? Eur Radiol 2005;15:1658-66.
79. 18F-FDG PET in patients with locally advanced rectal cancer previously treated with neoadjuvant radiochemotherapy. AJR Am J Roentgenol 2006;187:W202-8.
80. 18F-FDG PET scans after neoadjuvant chemoradiation provides prognostic stratification in patients with locally advanced rectal carcinoma subsequently treated by radical surgery. J Nucl Med 2006;47:14-22. (Pubitemid 46768507)
81. Kristiansen C, Loft A, Berthelsen AK, Graff J, Lindebjerg J, Bisgaard C et al. PET/CT and histopathologic response to preoperative chemoradiation therapy in locally advanced rectal cancer. Dis Colon Rectum 2008;51:21-5.
82. Vliegen RF, Beets-Tan RG, Vanhauten B, Driessen A, Oellers M, Kessels AG et al. Can an FDG-PET/CT Predict Tumor Clearance of the Mesorectal Fascia after Preoperative Chemoradiation of Locally Advanced Rectal Cancer? Strahlenther Onkol 2008;184:457-64.
83. Konski A, Li T, Sigurdson E, Cohen SJ, Small W, Jr., Spies S, et al. Use of molecular imaging to predict clinical outcome in patients with rectal cancer after preoperative chemotherapy and radiation. Int J Radiat Oncol Biol Phys 2008 [Epub ahead of print].
84. Amthauer H, Denecke T, Rau B, Hildebrandt B, Hunerbein M, Ruf J et al. Response prediction by FDG-PET after neoadjuvant radiochemotherapy and combined regional hyperthermia of rectal cancer: correlation with endorectal ultrasound and histopathology. Eur J Nucl Med Mol Imaging 2004;31:811-9. (Pubitemid 38758350)
85. Guillem JG, Moore HG, Akhurst T, Klimstra DS, Ruo L, Mazumdar M et al. Sequential preoperative fluorodeoxyglucose-positron emission tomography assessment of response to preoperative chemoradiation: a means for determining longterm outcomes of rectal cancer. J Am Coll Surg 2004;199:1-7.
86. Konski A, Hoffman J, Sigurdson E, Haluszka O, Engstrom P, Cheng JD et al. Can molecular imaging predict response to preoperative chemoradiation in patients with rectal cancer? A Fox Chase Cancer Center prospective experience. Semin Oncol 2005;32:S63-7.
87. Capirci C, Rampin L, Erba PA, Galeotti F, Crepaldi G, Banti E, et al. Sequential FDG-PET/CT reliably predicts response of locally advanced rectal cancer to neo-adjuvant chemo-radiation therapy. Eur J Nucl Med Mol Imaging 2007;34:1583-93.
88. Melton GB, Lavely WC, Jacene HA, Schulick RD, Choti MA, Wahl RL et al. Efficacy of preoperative combined 18-fluorodeoxyglucose positron emission tomography and computed tomography for assessing primary rectal cancer response to neoadjuvant therapy. J Gastrointest Surg 2007;11:961-9; discussion 9.
89. Siegel R, Dresel S, Koswig S, Gebauer B, Hunerbein M, Schneider W et al. Response to preoperative short-course radiotherapy in locally advanced rectal cancer: value of f-fluorodeoxyglucose positron emission tomography. Onkologie 2008;31:166-72.
90. 18F-FDG PET is an early predictor of pathologic tumor response to preoperative radiochemotherapy in locally advanced rectal cancer. J Nucl Med 2006;47:1241-8.
91. Rosenberg R, Herrmann K, Gertler R, Kunzli B, Essler M, Lordick F et al. The predictive value of metabolic response to preoperative radiochemotherapy in locally advanced rectal cancer measured by PET/CT. Int J Colorectal Dis 2009;24:191-200.
92. Nakagawa K, Yamashita H, Nakamura N, Igaki H, Tago M, Hosoi Y et al. Preoperative radiation response evaluated by 18-fluorodeoxyglucose positron emission tomography predicts survival in locally advanced rectal cancer. Dis Colon Rectum 2008;51:1055-60.
93. Guillem JG, Calle Jr JPL, Akhurst T, Tickoo S, Ruo L, Minsky BD et al. Prospective assessment of primary rectal cancer response to preoperative radiation and chemotherapy using 18-fluorodeoxyglucose positron emission tomography. Dis Colon Rectum 2000;43:18-24.
94. Haberkorn U, Strauss LG, Dimitrakopoulou A, Engenhart R, Oberdorfer F, Ostertag H et al. PET studies of fluorodeoxyglucose metabolism in patients with recurrent colorectal tumors receiving radiotherapy. J Nucl Med 1991;32:1485-90.
95. Kubota R, Yamada S, Kubota K, Ishiwata K, Tamahashi N, Ido T. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in viva high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med 1992;33:1972-80.
96. Antoch G, Vogt FM, Veit P, Freudenberg LS, Blechschmid N, Dirsch O et al. Assessment of liver tissue after radiofrequency ablation: findings with different imaging procedures. J Nucl Med 2005;46:520-5. (Pubitemid 43093165)
97. Joosten J, Jager G, Oyen W, Wobbes T, Ruers T. Cryosurgery and radiofrequency ablation for unresectable colorectal liver metastases. Eur J Surg Oncol 2005;31:1152-9.
98. Langenhoff BS, Oyen WJ, Jager GJ, Strijk SP, Wobbes T, Corstens FH et al. Efficacy of fluorine-18-deoxyglucose positron emission tomography in detecting tumor recurrence after local ablative therapy for liver metastases: a prospective study. J Clin Oncol 2002;20:4453-8.
99. Donckier V, Van Laethem JL, Goldman S, Van Gansbeke D, Feron P, Ickx B et al. [F-18] fluorodeoxyglucose positron emission tomography as a tool for early recognition of incomplete tumor destruction after radiofrequency ablation for liver metastases. J Surg Oncol 2003;84:215-23.
100. 18F-FDG incorporation corresponding to hexokinase activity and glucose transport. J Nucl Med 2008;49:1386-94.
101. Findlay M, Young H, Cunningham D, Iveson A, Cronin B, Hickish T et al. Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil. J Clin Oncol 1996;14:700-8. (Pubitemid 26085512)
102. de Geus-Oei LF, van Laarhoven HW, Visser EP, Hermsen R, van Hoorn BA, Kamm YJ et al. Chemotherapy response evaluation with FDG-PET in patients with colorectal cancer. Ann Oncol 2008;19:348-52.
103. Small RM, Lubezky N, Shmueli E, Figer A, Aderka D, Nakache R, et al. Response to chemotherapy predicts survival following resection of hepatic colo-rectal metastases in patients treated with neoadjuvant therapy. J Surg Oncol 2009;99;93-8.
104. Krak NC, Boellaard R, Hoekstra OS, Twisk JW, Hoekstra CJ, Lammertsma AA. Effects of ROI definition and reconstruction method on quantitative outcome and applicability in a response monitoring trial. Eur J Nucl Med Mol Imaging 2005;32:294-301.
105. 18F-FDG PET in malignant tumors. J Nucl Med 2008;49:1804-8.
106. Westerterp M, Pruim J, Oyen W, Hoekstra O, Paans A, Visser E et al. Quantification of FDG PET studies using standardised uptake values in multi-centre trials: effects of image reconstruction, resolution and ROI definition parameters. Eur J Nucl Med Mol Imaging 2007;34:392-404.
107. Boellaard R, Oyen WJ, Hoekstra CJ, Hoekstra OS, Visser EP, Willemsen AT et al. The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trials. Eur J Nucl Med Mol Imaging 2008;35:2320-33.